(CercleFinance.com) – GSK announced on Wednesday positive results from a phase III clinical study for its new oral antibiotic against gonorrhea, a sexually transmitted infection increasingly resistant to existing treatments.
The trial, specifies the British laboratory in a press release, showed that during a medical visit between three to seven days after the administration of the treatment, its gepotidacin was more effective (92.6%) than the current standard treatment. , based on the combination of intramuscular ceftriaxone and oral azithromycin (91.2%).
According to GSK, some 82 million new cases of gonorrhea are recorded each year, including 648,056 in the United States, the equivalent of a jump of 118% between 2009 and 2021 according to the CDC.
According to the latter, half of cases of gonorrhea today prove resistant to at least one antibiotic treatment.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
